Complaint letter to Health Canada: Pfizer "toe-tag" ad
January 22, 2004
Honourable Pierre S. Pettigrew
Minister of Health, Minister of Intergovernmental Affairs
and Minister responsible for Official Languages
House of Commons
Honourable Minister Pettigrew,
Should a pharmaceutical manufacturer be allowed to use misleading information on cardiovascular risks, and the Canadian public's understandable fear of death from heart disease, in order to promote sales of its product?
In August 2003, the Director and staff of the Essential Drugs and Medicines Policy Division at the World Health Organization (WHO) wrote a letter to the Lancet, calling on health authorities to, "urgently increase their vigilance with respect to drug promotion," citing a recent ad campaign financed by Pfizer in France to promote their cholesterol-lowering drug, atorvastatin (Lipitor). Dr. Jonathan Quick and his colleagues at WHO charged that the ad campaign, "contained misleading statements and omissions likely to induce medically unjustifiable drug use or to give rise to undue risks." 1
The same ad campaign has been running in Canada for at least 18 months in magazines and on television, and has been the subject of complaints to Advertising Standards Canada by members of the public. The Canadian version, although financed by Pfizer, only states that it is 'sponsored by one of Canada's research-based pharmaceutical companies'. This is in very fine print, with logos of the Canadian Lipid Nurses Network and the Canadian Diabetes Association more prominent. The television ad also fails to clearly state that it is financed by Pfizer. Thus in addition to presenting misleading information on cardiovascular risks – the same misleading information as in the French campaign – the fact that this is paid advertising by a pharmaceutical company is obscured.
Along with a recent copy of the ad (October/November 2003, Healthy Woman magazine), I am enclosing a complaint letter sent to Advertising Standards Canada (ASC) by Mr. Terence Young, ex Member of the Ontario Provincial Parliament, and the father of Vanessa Young, the 15-year old woman who died after taking cisapride (Propulsid). When he made his complaint, Mr. Young was told that if he went to the media this complaint would not be investigated. This is not the only complaint made to Advertising Standards Canada about this campaign.
We are very concerned that, whether investigated or not, the ad has continued to run for months, and there is no sign thus far of any regulatory action to prevent the company from running this ad or to correct the misinformation reaching the public.
What is the risk for Canadians? In exaggerating the risks of cholesterol among those without previous heart or vascular disease, the ad campaign also downplays much more important preventable risks, such as smoking, obesity and diabetes and neglects health promoting activities that are shown to be successful such as healthy eating, exercise, and stress reduction. In playing so dramatically on the public's anxieties, these ads will certainly lead to unnecessary drug use among those with no likelihood of benefit. The ad campaign conveys a claim that those without previous heart disease can avoid sudden deaths from heart attacks if they get their cholesterol tested and treated. This claim contradicts existing scientific evidence about what these treatments can and cannot do. A recent systematic review of clinical trials of cholesterol-lowering drugs for primary prevention found a small cardiovascular benefit and suggested no overall health benefit, in terms of serious morbidity, hospitalizations, disability or death. 2 Furthermore, small cardiovascular benefit was limited to middle-aged men and was absent for older men and women (28% of the population studied). 3 This is described in two recent Therapeutics Letters produced for British Columbia physicians and pharmacists, which we have enclosed.
Another risk for Canadians, is the misplaced use of public and private funds on this type of publicity -- and the extra health care services it generates -- when they could be allocated to more effective investments both in the health service sector and the health determinants sector.
We ask your department to take immediate regulatory action to stop this ad campaign and to impose sanctions to prevent future similar violations. Pfizer should also be required to finance a corrective advertising campaign within the same media and at the same intensity level as this campaign.
We would also appreciate feedback on the following:
- The steps your department intends to take to investigate this advertising campaign;
- The timeline for the investigation
- What will be done to avoid further public exposure to misleading messages from this ad campaign while it is under investigation;
- Any decisions that are made and conveyed to the company.
Thank you in advance for your assistance. Ensuring that the public is protected from misinformation on health and medical treatments – particularly misinformation that takes advantage of the public’s fear of death and disability – is a key regulatory function with important implications for public health.
If you have any questions or require further clarification or additional information, do not hesitate to get in touch with us.
- Quick, Jonathan D., et al, correspondence, The Lancet, Vol 362, Number 9385, 30 August 2003
- Do statins have a role in primary prevention? Therapeutics Letter #48, April-June, 2003. http//www.ti.ubc.ca/PDF/48.pdf
- Statin's benefit in secondary prevention confirmed: What is the optimal dosing strategy? Therapeutics Letter #49, July-September, 2003. http://www.ti.ubc.ca/PDF/49.pdf
Anne Rochon Ford
on behalf of the Steering Committee of Women and Health Protection:
Dr. Ken Bassett, University of British Columbia
Ms Sharon Batt, Dalhousie University
Ms. Madeline Boscoe, Canadian Women's Health Network
Dr. Joel Lexchin, York University
Dr. Abby Lippman, Canadian Women's Health Network
Dr. Fiona Miller, McMaster University
Dr. Barbara Mintzes, University of British Columbia
Ms. Laura Shea, Breast Cancer Action Montreal
and affiliated members of Women and Health Protection:
Wendy Armstrong, Consumers Association of Alberta
Dr. Rosanna Baraldi, DES Action Canada
Dr. Warren Bell, PharmaWatch
Wanda Cree, Seniors Community Health Council, Alberta
Janet Currie, PharmaWatch
Colleen Fuller, PharmaWatch
Brewster Kneen, Ram's Horn
Carol Kushner, PharmaWatch
Dr. Peter Mansfield, Healthy Skepticism, Australia
Michael McBane, Canadian Health Coalition
Kelsey Nortland, Simon Fraser University
Kathleen O'Grady, Concordia University
Dr. Jim Wright, Therapeutics Initiative, UBC
copy of ad Lancet letter Letter from Terence Young TI letter on statins and primary prevention cc: * Jonathan D. Quick, MD, MPH, Director, Essential Drugs and Medicines Policy (EDM), World Health Organization * Mr Terrence Young, Drug Safety Canada * Ms. Linda Nagel, President and CEO, Advertising Standards Canada * Dr. Chris Turner, Director, Marketed Health Products Directorate, Health Canada * Ms Anne Szukte-Fournier, Advertising Coordinator, Marketed Health Products Directorate, Health Canada * Mr. Ray Chepesiuk, Pharmaceutical Advertising Advisory Board * Ms. Deanna St. Prix-Alexander, Executive Director, Women's Health Bureau * Minister Pettigrew's constituency office
Copyright ©2006-2007 Women and Health Protection